Showing 6631-6640 of 8649 results for "".
- Market Scope: Improved Vitrectomy Machine Features Expected to Expand Retinal Treatmentshttps://modernod.com/news/market-scope-improved-vitrectomy-machine-features-expected-to-expand-retinal-treatments/2481617/Advancements in vitrectomy machine technology are expected to improve safety and efficacy and enable surgeons to reach a larger population of patients with retinal disease over the next 5 years, according to a Market Scope report. These advancements include small-incision vitrectomy, subretinal t
- Lumibird Medical Renames its Polish Subsidiary to Lumibird Medical Polskahttps://modernod.com/news/lumibird-medical-renames-its-polish-subsidiary-to-lumibird-medical-polska/2481613/Lumibird Medical Group has renamed its Polish subsidiary, Quantel Medical Polska, to Lumibird Medical Polska. After 5 years of existence, the Polish subsidiary, with a constant double-digit growth since its creation, has moved to a larger site in Warsaw. “
- BVI Completes Enrollment of Finevision HP IDE Clinical Studyhttps://modernod.com/news/bvi-completes-enrollment-of-finevision-hp-ide-clinical-study/2481581/BVI announced it has completed enrollment of its US Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal IOL, Finevision HP. The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, rand
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- Visionix Unveils Second Generation VX 650 Multimodal Screener at Vision Expo 2023https://modernod.com/news/visionix-unveils-second-generation-vx-650-multimodal-screener-at-vision-expo-2023/2481461/Visionix announces a new multimodal device update with its second-generation VX 650. Launched in 2021, the VX 650 is an advanced anterior segment analyzer with retinal imaging. The enhanced wavefront-based aberrometer's "quick mode" and new capture flexibilities can decrease screeni
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Studyhttps://modernod.com/news/skye-bioscience-receives-positive-safety-review-of-sbi-100-ophthalmic-emulsion-after-second-cohort-of-phase-1-study/2481432/Skye Bioscience has received a positive recommendation following a prespecified data review by the safety review committee based on dosing of the second cohort of eight healthy participants of its phase 1 study of SBI-100 ophthalmic emulsion. The SRC has recommended that the trial conti
- Notal Vision: Clinical Trials Demonstrate Value of Home OCThttps://modernod.com/news/notal-vision-clinical-trials-demonstrate-value-of-home-oct/2481429/Notal Vision reported that the latest data on its investigational home-based optical coherence tomography (OCT) and how the service can be used to manage wet age-related macular degeneration (AMD) were recently presented at the Angiogenesis, Exudation, and Degeneration and Macula Society 202
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Radiance Therapeutics to Present at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/radiance-therapeutics-to-present-at-glaucoma-360-new-horizons-forum/2481398/Radiance Therapeutics announced that Laurence Marsteller, MD, Chief Executive Officer, will present the company at the Glaucoma Research Foundation headline event, Glaucoma 360 New Horizons 2023, that will take place on February 3, 2023 in San Francisco. The Radiance Therapeut